Oxatomide for stable asthma in adults and children

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 6, 2003, Pages

  Hayashi, Keiji ^a   Yanagi, Motokazu ^b   Wood Baker, Richard ^c   Takamatsu, Isamu IT ^d   Anami, Keiko KA ^e  

^a Hayashi Shyonika   (Japan)

^b TEZUKAYAMA UNIVERSITY   (Japan)

^c UNIVERSITY OF TASMANIA   (Australia)

^d OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^e TAKATSUKI RED CROSS HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; OXATOMIDE; PIPERAZINE DERIVATIVE;

ADULT; ASTHMA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; HUMANS; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS;

EID: 18744433580     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD002179     Document Type: Review

References (30)

1. Banham SW, Moran F. A clinical trial of oxatomide in asthma. British Journal of Clinical Practice 1980;34(11-12):323-6.
2. Brompton Hospital/Medical reserch council collaborative trial. A controlled trial of oxatomide in the treatment of asthma with or without perennial rhinitis. Clinical Allergy 1981;11:483-90.
3. Chiu C-P, Huang J-L, Lin T-Y, Shieh W-B, Hsieh K-H. Double-blind placebo-controlled study of oxatomide in the treatment of childhood asthma. Acta Paediatrica Sinica 1997;38(1):14-20.
4. Giorgi PL, Oggiano N, Kantar A, Coppa GV, Nicora M. Protective effect of oxatomide in infantile bronchial asthma. Double-blind study vs placebo [Effetto protettivo dell'oxatomide sull'asma bronchiale infantaile]. Minerva Pediatrica 1998;50(7-8):339-46.
5. Kawakami Y, Takahashi S, et al. Clinical evaluation of an oral anti-allergic agent KW-4354 (oxatomide) in adult bronchial asthma [Keikou Kou Arerugii Zai KW-4354 (Oxatomide) no Kikansizensoku ni Taisuru Rinsyou Hyouka]. Yakuri to Tiryou 1984;12(6):2503-41.
6. Samanek M. Spirometric evaluation of oxatomide in asthma children. A double-blind placebo-controlled study. Janssen research products information service, Clinical Research Report 1978; Vol. Serial Number: R3544/13, N15422.
7. Bianchi G. Treatment of asthma syndromes in pediatric patients using a combination of a beta2-stimulant and a histamine antagonist. International Journal of Clinical Pharmacology, Therapy, & Toxicology 1985;23(1):56-8.
8. Ciprandi G, et al. Oxatomide reduces inflammatory events induced by allergen-specific conjunctival challenge. Annals of Allergy, Asthma, & Immunology 1995;75(5):446-52.
9. De Beule R, Vannieuwenhuyse E, Callier J, Verstraete W, Degreef F, Gregoire M, Robience Y, Stevens W, Libert P. Placebo-controlled clinical evaluation of oxatomide (R 35443). A novel potent anti-allergic drug in the treatment of hay fever. Acta Allergologica 1977;32:278-89.
10. De Cree J, Verhaegen H, Geulens H. Exercise-induced asthma. The comparative acute effects of oxatomide, placebo and sodium cromoglycate. Clinical Trials Journal 1980;17(3):84-9.
11. De Benedictis FM, Forenza N, Armenio L, Boner AL, Giorgi PL, Del Giudice MM, et al. Efficacy and safety of cetirizine and oxatomide in young children with perennial allergic rhinitis: A 10 day, multicenter, double-blinded, randomized, parallel-group study. Pediatric Asthma, Allergy and Immunology 1997;11(2):119-28.
12. Evans Y. Allergies: New treatment options and studies. Drug Topics 1999;143(11 Suppl):10s-15s.
13. Fujimori K, Suzuki E, Arakawa M. Effects of oxatomide, H1-antagonist, on post infectious chronic cough; a comparison of oxatomide combined with dextromethorphan versus dextromethorphan alone [Kaze Shyoukougun go Mansei Gaisou ni Taisuru Histamin (H1) Juyoutai Kikkouyaku, Okisatomido no Kouka]. Arerugii 1998;47(1):48-53.
14. Gasbarrini G, Addolorato G, Castelli E, et al. Oxatomide in food allergies. Comparative study versus disodium chromoglycate. International Journal of Immunopathology & Pharmacology 1998;11(3):149-54.
15. Kishida M, Sasamoto A, Saito S, Iikura Y. Oxatomide modifies methacholine- and exercise-induced bronchoconstriction in asthmatic children. Annals of Allergy 1992;69(5):455-61.
16. Nakamura T, et al. Clinical evaluation of oxatomide dry syrop for brondhial asthma [Kikanshi Zensoku ni Taisuru Shin Keikou Kou Arerugii Zai Okisatomido Dorai Shiroppu no Rinshou Hyouka]. Shyounika Rinsyou 1984;37(2):423-35.
17. Noma T, Yoshizawa L, Kawano Y, Nakajima T. Effect of oxatomide on T-cell activation and the production of interferon-gamma in mite sensitive asthma. European Journal of Pharmacology 1998;343(2-3):239-47.
18. Petella V, De Crescenzo G, Marino O, Spadaro G, Genovese A, Marone G. Oxatomide inhibits the release of proinflammatory mediators from human basophils and mast cells. International Archives of Allergy & Immunology 1996;111(1):23-9.
19. Scremin S, Caprioglio L. Treatment of asthma with an extempore combination of a bronchodilator, salbutamol, and a new antihistamine drug, oxatomide. International Journal of Clinical Pharmacology Research 1986;6(2):105-11.
20. Shindo KI, Fukumura M. Oxatomide inhibits synthesis and release of platelet-activationg factor in human neurotrophils. Prostaglandins Leukotrienes & Essential Fatty Acids 1998;58(2):99-104.
21. Silverman M, Toolery M. Oxatomide and exercise-induced asthma in children: the value of serial exercise tests. Clinical Allergy 1981;11(5):421-8.
22. Simons FE. Is antihistamine (H1-receptor antagonist) therapy useful in clinical asthma?. Clinical & Expreimental Allergy 1999;Suppl 29(3):98-104.
23. Tomaselli V, Paolino G, Pistorio MP, Vancheri C, Crimi N. Protective effect of oxatomide in immediate and delayed response after specific bronchilal provocation test. Double blind cross-over study vs placebo [Valutazinone della protezione esplicata dall'oxatomide sulla rispostaimmediata e tardiva dopo test di provocazione bronchiale specifica. Studio in doppio cieco cross-over versus placebo]. Archivio di Medicina Interna 1997;49(1-2):37-47.
24. Akamatsu H, Miyachi Y, Asada Y, Niwa Y. The effect of oxatomide on neutrophil oxgen radical generation. Biological & Pharmaceutical Bulletin 1993;16(6):568-70.
25. International asthma management project. International consensus report on diagnosis and management of asthma. Allergy 1992;47(13 Suppl):1-61.
26. Hayashi K, Hama R. Evaluation of oral anti-allergic drugs in Japan. Lancet 1996;347(8999):477.
27. Jadad AR, Moore RA, Carroll D, Jenkinson C, Raynolds JM, Gavaghan DJ, et al. Assessing the quality of reports on randomized clinical trials: Is blinding necessary?. Controlled Clinical Trials 1996;134(17):1-12.
28. Manabe H, Ohmori K, Tomioka H, Yoshida S. Oxatomide inhibits the release of chemical mediators from human lung tissues and from granulocytes. International Archives of Allergy & Applied Immunology 1988;87(1):91-7.
29. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. JAMA 1995;273(5):408-12.
30. Van Ganse E, Kaufman L, Derde MP, Yernault JC, Delaunois L, Vincken W. Effects of antihistamines in adult asthma: a meta-analysis of clinical trials. European Respiratory Journal 1997;10:2216-24.